Fort Worth, TX, United States of America

Keith Goldan

This inventor holds 1 USPTO granted patent. Top assignee: Urgo US, Inc.. Active years: 2020.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Keith Goldan: Innovator in Infection and Inflammation Treatment

Introduction

Keith Goldan is a notable inventor based in Fort Worth, TX (US). He has made significant contributions to the field of medical treatments, particularly focusing on conditions associated with infection and inflammation. His innovative approach has led to the development of effective methods and compositions that address these health issues.

Latest Patents

Goldan holds 1 patent for his invention titled "Methods and compositions for treating conditions associated with infection and/or inflammation." This patent presents methods and compositions aimed at treating and preventing conditions characterized by infection and/or inflammation, especially in the eyes, ears, nose, and throat. The invention involves administering hypohalous acid to patients, showcasing a novel approach to managing these conditions.

Career Highlights

Throughout his career, Goldan has been associated with Urgo Us, Inc., where he has applied his expertise in developing innovative medical solutions. His work has been instrumental in advancing treatment options for patients suffering from various infections and inflammatory conditions.

Collaborations

Goldan collaborates with Claire Sampson, contributing to a dynamic team focused on medical innovation. Their combined efforts aim to enhance the effectiveness of treatments available in the healthcare sector.

Conclusion

Keith Goldan's contributions to the field of medical treatments for infection and inflammation highlight his role as an innovative inventor. His patent reflects a commitment to improving patient care through advanced methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…